Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Expenses: 2018-2024

Historic Accumulated Expenses for Bicycle Therapeutics (BCYC) over the last 7 years, with Dec 2024 value amounting to $41.2 million.

  • Bicycle Therapeutics' Accumulated Expenses rose 12.86% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 12.86%. This contributed to the annual value of $41.2 million for FY2024, which is 30.90% up from last year.
  • As of FY2024, Bicycle Therapeutics' Accumulated Expenses stood at $41.2 million, which was up 30.90% from $31.5 million recorded in FY2023.
  • In the past 5 years, Bicycle Therapeutics' Accumulated Expenses registered a high of $41.2 million during FY2024, and its lowest value of $11.6 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $33.1 million, with a median of $31.5 million in 2023.
  • Data for Bicycle Therapeutics' Accumulated Expenses shows a peak YoY spiked of 89.27% (in 2020) over the last 5 years.
  • Over the past 5 years, Bicycle Therapeutics' Accumulated Expenses (Yearly) stood at $11.6 million in 2020, then rose by 22.49% to $14.2 million in 2021, then spiked by 85.71% to $26.5 million in 2022, then climbed by 19.12% to $31.5 million in 2023, then skyrocketed by 30.90% to $41.2 million in 2024.